The Epstein Barr virus is an oncogenic herpesvirus that is intimately involved in a number of malignancies in humans. The genetic basis of EBV associated oncogenesis is the concerted action of EBV latency associated genes and varying cellular genetic alterations. In immuno-competent individuals minimal EBV latency gene expression can be tolerated due to the high immunogeneticity of several of the EBV encoded latency gene products. In AIDS patients, however, expression of the full repriotrore of latency genes can sometimes be tolerated and therefore fewer cellular genetic alterations are required to give rise to malignant cell populations. This likely explains in part, the greatly increased susceptibility of AIDS patients to EBV associated non-Hodgkin's lymphomas. Unlike KSHV associated malignancies, the use of HAART therapy in AIDS patients has had a minimal influence on the number of AIDS/EBV associated non-Hodgkin's lymphomas. An array of publications in the last few years have provided compelling evidence that the small non-coding RNA genes referred to as microRNAs (miRNAs) not only play important roles in normal cellular signaling but that they are also key players in a wide array of cancers. Based on previous studies showing that EBV latency associated gene products signal through the activation of gene expression and based on the accumulating evidence indicating the role of miRNAs in cellular signaling, we hypothesize that latency associated viral gene products influence cellular miRNA gene expression. We further hypothesize that alterations in cellular miRNA expression profiles regulate key signal transduction pathways that influence the life cycle of the virus and may play a role in EBV associated oncogenesis in AIDS patients.
EBV is associated with a number of human cancers including nasopharyngeal carcinoma, Hodgkin's disease, Burkitt's lymphoma as well as a number of B-cell lymphomas in AIDS patients. Our studies are principally aimed at addressing the role of type III viral latency gene products on cellular miRNA gene expression and how this may influence the host cell environment to facilitate the life cycle of the virus and to influence EBV mediated oncogenesis in AIDS and transplant patients.
|Xu, Guorong; Strong, Michael J; Lacey, Michelle R et al. (2014) RNA CoMPASS: a dual approach for pathogen and host transcriptome analysis of RNA-seq datasets. PLoS One 9:e89445|
|Lin, Zhen; Wang, Xia; Strong, Michael J et al. (2013) Whole-genome sequencing of the Akata and Mutu Epstein-Barr virus strains. J Virol 87:1172-82|
|Concha, Monica; Wang, Xia; Cao, Subing et al. (2012) Identification of new viral genes and transcript isoforms during Epstein-Barr virus reactivation using RNA-Seq. J Virol 86:1458-67|
|Lin, Zhen; Puetter, Adriane; Coco, Joseph et al. (2012) Detection of murine leukemia virus in the Epstein-Barr virus-positive human B-cell line JY, using a computational RNA-Seq-based exogenous agent detection pipeline, PARSES. J Virol 86:2970-7|
|Nguyen, Hong T; Li, Cui; Lin, Zhen et al. (2012) The microRNA expression associated with morphogenesis of breast cancer cells in three-dimensional organotypic culture. Oncol Rep 28:117-126|
|Lin, Zhen; Flemington, Erik K (2011) miRNAs in the pathogenesis of oncogenic human viruses. Cancer Lett 305:186-99|
|Deng, Nan; Puetter, Adriane; Zhang, Kun et al. (2011) Isoform-level microRNA-155 target prediction using RNA-seq. Nucleic Acids Res 39:e61|
|Xu, Guorong; Fewell, Claire; Taylor, Christopher et al. (2010) Transcriptome and targetome analysis in MIR155 expressing cells using RNA-seq. RNA 16:1610-22|
|Lin, Zhen; Xu, Guorong; Deng, Nan et al. (2010) Quantitative and qualitative RNA-Seq-based evaluation of Epstein-Barr virus transcription in type I latency Burkitt's lymphoma cells. J Virol 84:13053-8|
|Yin, Qinyan; Wang, Xia; Fewell, Claire et al. (2010) MicroRNA miR-155 inhibits bone morphogenetic protein (BMP) signaling and BMP-mediated Epstein-Barr virus reactivation. J Virol 84:6318-27|
Showing the most recent 10 out of 13 publications